JP2017522025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522025A5 JP2017522025A5 JP2017502212A JP2017502212A JP2017522025A5 JP 2017522025 A5 JP2017522025 A5 JP 2017522025A5 JP 2017502212 A JP2017502212 A JP 2017502212A JP 2017502212 A JP2017502212 A JP 2017502212A JP 2017522025 A5 JP2017522025 A5 JP 2017522025A5
- Authority
- JP
- Japan
- Prior art keywords
- oncolytic virus
- virus
- activity
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306153 | 2014-07-16 | ||
| EP14306153.9 | 2014-07-16 | ||
| PCT/EP2015/066263 WO2016008976A1 (en) | 2014-07-16 | 2015-07-16 | Oncolytic virus for expression of immune checkpoint modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020163305A Division JP7077377B2 (ja) | 2014-07-16 | 2020-09-29 | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522025A JP2017522025A (ja) | 2017-08-10 |
| JP2017522025A5 true JP2017522025A5 (enExample) | 2018-08-16 |
| JP6895374B2 JP6895374B2 (ja) | 2021-06-30 |
Family
ID=51220528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502212A Active JP6895374B2 (ja) | 2014-07-16 | 2015-07-16 | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
| JP2020163305A Active JP7077377B2 (ja) | 2014-07-16 | 2020-09-29 | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020163305A Active JP7077377B2 (ja) | 2014-07-16 | 2020-09-29 | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10555981B2 (enExample) |
| EP (2) | EP3169341B1 (enExample) |
| JP (2) | JP6895374B2 (enExample) |
| CN (2) | CN120555373A (enExample) |
| AU (2) | AU2015289125B2 (enExample) |
| CA (2) | CA2954841A1 (enExample) |
| DK (2) | DK3169341T3 (enExample) |
| ES (2) | ES2743873T3 (enExample) |
| HU (1) | HUE045108T2 (enExample) |
| IL (1) | IL250058A0 (enExample) |
| PL (1) | PL3169341T3 (enExample) |
| PT (1) | PT3169341T (enExample) |
| RU (1) | RU2696312C2 (enExample) |
| WO (1) | WO2016008976A1 (enExample) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210008155A (ko) * | 2012-08-30 | 2021-01-20 | 암젠 인크 | 단순 헤르페스 바이러스 및 면역 체크포인트 억제제를 사용한 흑색종의 치료방법 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| ES2833425T3 (es) * | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| RU2696312C2 (ru) * | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| AU2015335607B2 (en) | 2014-10-24 | 2020-04-23 | Calidi Biotherapeutics (Nevada), Inc. | Combination immunotherapy approach for treatment of cancer |
| CN115300622A (zh) | 2015-02-25 | 2022-11-08 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合 |
| CN121159719A (zh) | 2015-04-17 | 2025-12-19 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| MA53355A (fr) | 2015-05-29 | 2022-03-16 | Agenus Inc | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
| EP3314025A4 (en) * | 2015-06-29 | 2019-04-24 | Regents of the University of Minnesota | APOBEC3B MUTAGENESIS AND IMMUNOTHERAPY |
| EP3313993A4 (en) | 2015-06-29 | 2019-06-19 | Regents of the University of Minnesota | ANTI-APOBEC3 ANTIBODIES AND METHOD OF PREPARATION AND USE |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| CN108135996B (zh) | 2015-08-11 | 2022-06-21 | 卡利迪生物治疗有限公司 | 用以癌症治疗的天花疫苗 |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| CA3008279A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| WO2017112894A1 (en) | 2015-12-22 | 2017-06-29 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| US10612005B2 (en) | 2016-01-08 | 2020-04-07 | Replimune Limited | Modified oncolytic virus |
| CN108883132A (zh) * | 2016-01-22 | 2018-11-23 | X4 制药有限公司 | 用于治疗癌症的方法 |
| KR20180136435A (ko) | 2016-01-27 | 2018-12-24 | 온코루스, 인크. | 종양 살상형 바이러스 벡터 및 그의 용도 |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| KR20180133395A (ko) | 2016-02-25 | 2018-12-14 | 메모리얼 슬로안 케터링 캔서 센터 | 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스 |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| US11414491B2 (en) | 2016-05-18 | 2022-08-16 | Mayo Foundation For Medical Education And Research | Targeting PD-L1 on tumor cells |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| EP3472129A4 (en) | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| AU2017290828A1 (en) | 2016-06-30 | 2019-01-24 | Virogin Biotech Canada Ltd | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| EP3486322B1 (en) * | 2016-07-13 | 2021-09-29 | National University Corporation Tottori University | Method for producing vaccinia virus expressing foreign gene |
| EP3494219A1 (en) * | 2016-08-03 | 2019-06-12 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
| WO2018049248A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
| US20190275092A1 (en) | 2016-11-01 | 2019-09-12 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
| DK3551660T5 (da) | 2016-12-07 | 2024-09-02 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| KR20190112263A (ko) * | 2016-12-12 | 2019-10-04 | 멀티비르 인코포레이티드 | 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물 |
| US11298420B2 (en) * | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
| CN108261426B (zh) | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| GB201700350D0 (en) * | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| EP3573632B1 (en) * | 2017-01-30 | 2024-08-07 | EpicentRx, Inc. | Tumor selective tata-box and caat-box mutant oncolytic viruses |
| CN119236118A (zh) * | 2017-02-28 | 2025-01-03 | 基因药物株式会社 | 含肿瘤特异性溶瘤腺病毒和免疫检查点抑制剂的抗癌组合物 |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| WO2018218137A1 (en) | 2017-05-25 | 2018-11-29 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| US11612625B2 (en) | 2017-07-26 | 2023-03-28 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| CN109576231B (zh) * | 2017-09-28 | 2022-03-25 | 北京康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| BR112020007542A2 (pt) | 2017-10-18 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados |
| AU2018355519A1 (en) * | 2017-10-27 | 2020-03-26 | Amgen Inc. | Compositions and methods for treating liver cancer |
| EP3710018A4 (en) * | 2017-11-16 | 2022-03-09 | Virogin Biotech Canada Ltd | ONCOLYTIC VIRUSES DECORATED BY A TARGETING FRACTION |
| CN108165536A (zh) * | 2017-12-11 | 2018-06-15 | 浙江大学 | 一种重组溶瘤痘苗病毒及其制备方法与应用 |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| SG11202006457YA (en) | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
| BR112020014727A2 (pt) * | 2018-01-19 | 2020-12-08 | Kolon Life Science, Inc. | Vírus vaccinia recombinante e composição farmacêutica compreendendo o mesmo |
| WO2019148109A1 (en) | 2018-01-26 | 2019-08-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Expression of metabolic modulators in tumor microenvironment to improve tumor therapy |
| WO2019151836A1 (en) * | 2018-02-05 | 2019-08-08 | Sillajen, Inc. | Oncolytic vaccinia virus expressing an immune checkpoint protein antagonist to treat cancer |
| WO2019168346A1 (ko) * | 2018-02-28 | 2019-09-06 | 주식회사 바이오녹스 | 항암바이러스 및 히드록시유레아를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 |
| CN108329378B (zh) * | 2018-03-12 | 2020-09-25 | 华中农业大学 | 塞内卡谷病毒vp1蛋白、编码基因、杂交瘤细胞株和单克隆抗体及其应用 |
| CA3093696A1 (en) * | 2018-03-13 | 2019-09-19 | Memorial Sloan Kettering Cancer Center | Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy |
| WO2020036635A2 (en) | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| MX2021001883A (es) * | 2018-08-16 | 2021-07-15 | Musc Found For Res Dev | Virus recombinantes del mixoma y usos de los mismos. |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| EP3617230A1 (en) * | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| WO2020052551A1 (en) * | 2018-09-10 | 2020-03-19 | Genesail Biotech (Shanghai) Co. Ltd. | A modified oncolytic virus, composition and use thereof |
| MX2021003013A (es) | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| CN111100846A (zh) * | 2018-10-26 | 2020-05-05 | 上海元宋生物技术有限公司 | 表达pd-1结合蛋白的溶瘤病毒及其应用 |
| WO2020092850A1 (en) * | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
| JP7646542B2 (ja) * | 2018-11-01 | 2025-03-17 | バイオインベント インターナショナル アクティエボラーグ | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
| CA3116192C (en) | 2018-11-06 | 2025-09-23 | Calidi Biotherapeutics (Nevada), Inc. | IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY |
| EP4079750A3 (en) | 2018-11-21 | 2023-01-04 | Mayo Foundation for Medical Education and Research | Adenoviruses and methods for using adenoviruses |
| CN109627336A (zh) * | 2018-12-20 | 2019-04-16 | 南京昂科利医药科技创新研究院有限公司 | 一种表达pd-l1单链抗体的新城疫溶瘤病毒的制备方法及应用 |
| EP3898997A4 (en) * | 2018-12-21 | 2022-11-16 | Ottawa Hospital Research Institute | MODIFIED ORTHOPOXVIRUS VECTORS |
| US20220056481A1 (en) | 2018-12-28 | 2022-02-24 | Transgene | M2-defective poxvirus |
| CA3125370A1 (en) * | 2019-01-29 | 2020-08-06 | Arno Thaller | Recombinant oncolytic newcastle disease viruses with increased activity |
| CN109913425B (zh) * | 2019-03-22 | 2021-05-11 | 中国人民解放军总医院第五医学中心 | 一种重组流感病毒拯救方法及其在肿瘤治疗中的应用 |
| EP3946373A4 (en) * | 2019-03-28 | 2023-01-11 | Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University | ONCOLYTIC MYXOMA VIRUS EXPRESSING FAST P14 FOR TREATING BLOOD CANCER |
| CN113710694A (zh) | 2019-04-29 | 2021-11-26 | 梅奥医学教育及研究基金会 | 用于治疗癌症的多价pd-l1结合化合物 |
| WO2020237050A1 (en) | 2019-05-22 | 2020-11-26 | Leidos, Inc. | Lag3 binding peptides |
| BR112022000928A2 (pt) | 2019-07-19 | 2022-03-08 | Seneca Therapeutics Inc | Terapia oncolítica do vírus seneca valley de segunda geração: composições e métodos da mesma |
| CA3150829A1 (en) * | 2019-08-26 | 2021-03-04 | Bionoxx Inc. | Pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredient for treatment of cancer |
| WO2021116943A1 (en) * | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| CA3168771A1 (en) * | 2020-02-20 | 2021-08-26 | Eric Bartee | Recombinant myxoma viruses and uses thereof |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| EP4162951A4 (en) * | 2020-06-05 | 2024-07-10 | Shanghai Bao Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMPOSITION OF ENZYMES AND VIRUSES AND ASSOCIATED APPLICATION |
| AU2021316230A1 (en) | 2020-07-31 | 2023-03-16 | Leidos, Inc. | LAG3 binding peptides |
| EP4225444A1 (en) | 2020-10-12 | 2023-08-16 | Leidos, Inc. | Immunomodulatory peptides |
| CA3197069A1 (en) * | 2020-10-13 | 2022-04-21 | Immunovaccine Technologies Inc. | Methods of treating diffuse large b-cell lymphoma |
| EP4249596A4 (en) * | 2020-11-17 | 2025-03-12 | National University Corporation Tottori University | NEW GENE RECOMBINANT VACCINIAVIRUS AND USE THEREOF |
| CN112641798A (zh) * | 2020-12-29 | 2021-04-13 | 武汉博威德生物技术有限公司 | 一种提高重组柯萨奇病毒溶瘤作用的方法 |
| CA3207860A1 (en) * | 2021-01-11 | 2022-07-14 | Seneca Therapeutics, Inc. | Seneca valley virus combination therapy to treat a cancer refractory to a checkpoint inhibitor |
| EP4281549A4 (en) * | 2021-01-19 | 2025-05-07 | Seneca Therapeutics, Inc. | ONCOLYTIC THERAPY COMPOSITIONS CONTAINING SENECA VALLEY VIRUS AND METHODS THEREFOR |
| JP2024505274A (ja) * | 2021-02-02 | 2024-02-05 | ゲオバックス インコーポレイテッド | ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト |
| US20240067936A1 (en) * | 2021-02-26 | 2024-02-29 | Sillajen, Inc. | Oncolytic virus and uses thereof |
| CN114934065A (zh) * | 2021-11-25 | 2022-08-23 | 浙江理工大学绍兴生物医药研究院有限公司 | 携带免疫检查点分子tim-3抗体基因的溶瘤腺病毒构建方法和应用 |
| CN120648657A (zh) * | 2024-03-08 | 2025-09-16 | 上海锦斯生物技术有限公司 | 一种修饰的溶瘤病毒及其组合物 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5856153A (en) | 1994-11-17 | 1999-01-05 | Cayla | Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| WO1998056415A1 (en) | 1997-06-11 | 1998-12-17 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6322980B1 (en) | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP5118798B2 (ja) | 2000-03-07 | 2013-01-16 | メルク・シャープ・エンド・ドーム・コーポレイション | アデノウイルス製剤 |
| US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
| GB0128288D0 (en) | 2001-11-27 | 2002-01-16 | Siddall & Hilton Ltd | Spring location means |
| CA2467365C (en) | 2001-12-10 | 2012-11-20 | Bavarian Nordic A/S | Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| DE60317677T2 (de) | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| JP4672659B2 (ja) | 2003-07-21 | 2011-04-20 | トランジェーヌ、ソシエテ、アノニム | 改善されたシトシンデアミナーゼ活性を有するポリペプチド |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| JP2008519590A (ja) * | 2004-11-12 | 2008-06-12 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 組換えニューカッスル病ウィルス |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| CA2611861C (en) | 2005-06-08 | 2017-11-28 | The Brigham And Women's Hospital, Inc. | Methods and compositions for the treatment of persistent infections |
| KR101357685B1 (ko) | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
| WO2007123737A2 (en) | 2006-03-30 | 2007-11-01 | University Of California | Methods and compositions for localized secretion of anti-ctla-4 antibodies |
| MX2008016036A (es) | 2006-06-20 | 2009-04-07 | Transgene Sa | Vacuna viral recombinante. |
| DK2029756T3 (en) | 2006-06-20 | 2017-02-13 | Transgene Sa | PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| JP2010526546A (ja) | 2007-05-14 | 2010-08-05 | バヴァリアン・ノルディック・アクティーゼルスカブ | ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製 |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| RU2503717C2 (ru) * | 2007-11-19 | 2014-01-10 | Трансжене Са | Поксвирусные онколитические векторы |
| US9687515B2 (en) * | 2007-11-19 | 2017-06-27 | Transgene S.A. | Poxviral oncolytic vectors |
| HRP20150360T1 (hr) | 2007-11-19 | 2015-05-08 | Transgene Sa | Poksvirusni onkolitiäśki vektori |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| CN102257134B (zh) | 2008-02-12 | 2014-03-05 | 赛诺菲巴斯德有限公司 | 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| US8609392B2 (en) | 2009-05-12 | 2013-12-17 | Transgene S.A. | Method for orthopoxvirus production and purification |
| MX374075B (es) | 2010-03-26 | 2025-03-05 | Dartmouth College | Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos. |
| EP2739293B1 (en) | 2011-08-05 | 2020-06-10 | SillaJen Biotherapeutics, Inc. | Methods and compositions for production of vaccina virus |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| AU2013296919A1 (en) | 2012-07-30 | 2015-01-22 | Alex Wah Hin Yeung | Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| RU2696312C2 (ru) * | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| CN108165536A (zh) * | 2017-12-11 | 2018-06-15 | 浙江大学 | 一种重组溶瘤痘苗病毒及其制备方法与应用 |
| CA3093696A1 (en) * | 2018-03-13 | 2019-09-19 | Memorial Sloan Kettering Cancer Center | Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy |
| EP3617230A1 (en) * | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| CN110218707B (zh) * | 2019-05-29 | 2021-10-22 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
-
2015
- 2015-07-16 RU RU2017103162A patent/RU2696312C2/ru active
- 2015-07-16 WO PCT/EP2015/066263 patent/WO2016008976A1/en not_active Ceased
- 2015-07-16 ES ES15738359T patent/ES2743873T3/es active Active
- 2015-07-16 PT PT15738359T patent/PT3169341T/pt unknown
- 2015-07-16 CA CA2954841A patent/CA2954841A1/en active Pending
- 2015-07-16 EP EP15738359.7A patent/EP3169341B1/en active Active
- 2015-07-16 HU HUE15738359A patent/HUE045108T2/hu unknown
- 2015-07-16 JP JP2017502212A patent/JP6895374B2/ja active Active
- 2015-07-16 CN CN202510690099.0A patent/CN120555373A/zh active Pending
- 2015-07-16 US US15/325,562 patent/US10555981B2/en active Active
- 2015-07-16 CA CA3190510A patent/CA3190510A1/en active Pending
- 2015-07-16 ES ES19174121T patent/ES2909957T3/es active Active
- 2015-07-16 DK DK15738359.7T patent/DK3169341T3/da active
- 2015-07-16 DK DK19174121.4T patent/DK3552615T3/da active
- 2015-07-16 CN CN201580050076.8A patent/CN107208069A/zh active Pending
- 2015-07-16 PL PL15738359T patent/PL3169341T3/pl unknown
- 2015-07-16 EP EP19174121.4A patent/EP3552615B8/en active Active
- 2015-07-16 AU AU2015289125A patent/AU2015289125B2/en active Active
-
2017
- 2017-01-11 IL IL250058A patent/IL250058A0/en active IP Right Grant
-
2019
- 2019-12-23 US US16/725,485 patent/US11779619B2/en active Active
-
2020
- 2020-01-24 AU AU2020200541A patent/AU2020200541B2/en active Active
- 2020-09-29 JP JP2020163305A patent/JP7077377B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522025A5 (enExample) | ||
| RU2017103162A (ru) | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек | |
| JP7667904B2 (ja) | インターロイキン－２－Ｆｃ融合タンパク質及び使用する方法 | |
| RU2017103151A (ru) | Комбинация онколитического вируса с модуляторами иммунологических контрольных точек | |
| Pol et al. | Trial Watch—Oncolytic viruses and cancer therapy | |
| JP2021527694A5 (enExample) | ||
| JP2019508017A (ja) | 抗ｔｃｒ複合体抗体又は断片をコードするウイルス | |
| JP2019500909A5 (enExample) | ||
| JP2021500932A5 (enExample) | ||
| US20200140563A1 (en) | Oncolytic virus and method | |
| CN110564767A (zh) | 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法 | |
| JP2022536929A5 (enExample) | ||
| CN116529258A (zh) | 白介素-2-Fc融合蛋白和使用方法 | |
| JP2023552289A5 (enExample) | ||
| JP2021522190A5 (enExample) | ||
| Zhang et al. | Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy | |
| US20250297002A1 (en) | Bispecific t-cell engager, recombinant oncolytic virus thereof, and use thereof | |
| JP2024517641A (ja) | 免疫細胞の遺伝子改変および治療的使用のための方法および組成物 | |
| EP4023232B1 (en) | Pharmaceutical composition for treating cancer comprising anticancer virus, immune checkpoint inhibitor and hydroxyurea as active ingredients | |
| EP3868876A1 (en) | New oncolytic newcastle disease viruses and recombinant ndv strains | |
| HK40096948A (zh) | 白介素-2-fc融合蛋白和使用方法 | |
| EP4703386A1 (en) | Antibody specifically binding to cd276, preparation method therefor and use thereof | |
| Zupko | Oncolytic viruses in cancer immunotherapy | |
| HK40012869A (en) | Oncolytic viruses and therapeutic molecules |